

Table 1: Baseline characteristics and outcomes for 171 HIV-infected patients receiving ART and either rifabutin or rifampicin for treatment of tuberculosis.

Variable		Groups	Rifabutin N=41 % (n)	Rifampicin N=130 % (n)	p value <sup>a</sup>
Baseline					
Age	Median [IQR], years		37.0 [32.4, 43.0]	35.9 [32.0, 43.0]	0.553*
Sex	Female		34.1 (14)	43.8 (57)	0.272
	Male		65.9 (27)	56.2 (73)	
Ethnic origin	White		39.0 (16)	23.1 (30)	0.003
	Black		41.5 (17)	70.0 (91)	
	Other		19.5 (8)	6.9 (9)	
HIV transmission	Homosexual		36.6 (15)	19.2 (25)	0.051
	Heterosexual		53.7 (22)	73.1 (95)	
	IVDU		9.8 (4)	7.7 (10)	
Hospital attended	Chelsea & Westminster		63.4 (26)	50.8 (66)	0.031
	University College London		36.6 (15)	49.2 (64)	
Type of ART	NNRTI		22.0 (9)	100.0 (130)	-
	PI		78.0 (32)	0.0 (0)	
Had TB in the past	No		92.7 (38)	90.0 (117)	0.764**
	Yes		7.3 (3)	10.0 (13)	
Type of TB Diagnosis	Confirmed		82.9 (34)	79.2 (103)	0.605
	Presumptive		17.1 (7)	20.8 (27)	
Time between HIV & TB diagnosis	Median [IQR], months		58 [3,108]	8 [0,54]	0.001*
Site of TB	Pulmonary		70.7 (29)	73.1 (95)	0.878**
	Lymph node		19.5 (8)	16.2 (21)	
	Disseminated		9.8 (4)	10.8 (14)	
Outcomes of treatment					
Duration of TB treatment	Median [IQR], months		6 [6,9]	6 [6,9]	0.634*
Completed TB regimen	Yes		87.8 (36)	96.9 (126)	0.037**
	No		12.2 (5)	3.1 (4)	
TB Treatment Interruption	Yes		25.0 (10)	17.7 (23)	0.307
	No		75.0 (30) <sup>b</sup>	82.3 (107)	
IRIS	Yes		29.3 (12)	12.3 (16)	0.012
	No		70.7 (29)	87.6 (112) <sup>c</sup>	
Change in CD4 count at end of TB treatment	Median [IQR], cells/mm <sup>3</sup>		75 [-12,241]	70 [8,170]	0.781*
HIV VL at end of TB treatment	Undetectable		87.5 (35)	78.6 (99)	0.256**
	Detectable		12.5 (5)	21.4 (27) <sup>d</sup>	
Died by end of treatment	Yes		2.4 (1)	2.3 (3)	1.000**

Key: <sup>a</sup>  $\chi^2$  test unless specified: \*Mann-Whitney U test: \*\* Fisher's exact test: <sup>b</sup> outcome not recorded for one patient: <sup>c</sup> outcome not recorded for two patients: <sup>d</sup> plasma HIV viral load result not available for one patient: IQR =interquartile range: IVDU =injecting drug user: ART =antiretroviral therapy: NNRTI =non-nucleoside reverse transcriptase inhibitor: PI =protease inhibitor: IRIS =immune reconstitution inflammatory syndrome: VL =plasma HIV viral load.